title: Impact of acute exposure to tobacco smoke on gelatinases in the bronchoalveolar space.
abstract: Clinical studies have indicated increased gelatinase activity in the airways of patients suffering from chronic obstructive pulmonary disease caused by tobacco smoke. The present study aimed to determine whether acute exposure to tobacco smoke per se causes a substantial and lasting impact on gelatinases and their inhibitors in the peripheral airways of atopic and nonatopic human subjects. Bronchoscopy with bronchoalveolar lavage (BAL) was performed on occasional smokers with and without atopy before and after smoking 10 cigarettes over a 48-h period. Samples from a group of never-smokers not exposed to tobacco smoke served as controls. Gelatinase identity and activity were measured using zymography, and gelatinase activity assay and concentrations of matrix metalloproteinase (MMP)-2, MMP-9, tissue inhibitor of MMP (TIMP)-1 and TIMP-2 were measured using ELISA. The results revealed no pronounced changes in identity, net activity or concentration of the gelatinases or changes in concentrations of TIMP-1 and TIMP-2 in BAL fluid before and after acute exposure to tobacco smoke. In conclusion, the present experimental study indicates that acute exposure to tobacco smoke does not cause any substantial impact on gelatinases or their inhibitors in the peripheral airways, irrespective of atopy status, a finding that is compatible with the fact that it takes many years of tobacco smoking to establish chronic obstructive pulmonary disease.
authors.affiliation: Lung Immunology Group, Dept of Internal Medicine/Respiratory Medicine and Allergology, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden. Pernilla.Glader@gu.se
authors.forename: P
authors.initials: P
authors.lastname: Glader
authors.forename: B
authors.initials: B
authors.lastname: Eldh
authors.forename: S
authors.initials: S
authors.lastname: Bozinovski
authors.forename: K
authors.initials: K
authors.lastname: Andelid
authors.forename: M
authors.initials: M
authors.lastname: Sjöstrand
authors.forename: C
authors.initials: C
authors.lastname: Malmhäll
authors.forename: G P
authors.initials: GP
authors.lastname: Anderson
authors.forename: G C
authors.initials: GC
authors.lastname: Riise
authors.forename: I
authors.initials: I
authors.lastname: Qvarfordt
authors.forename: A
authors.initials: A
authors.lastname: Lindén
mesh_terms: D000328:Adult; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry*; D005260:Female; D018093:Gelatinases / Q000187:drug effects; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000187:drug effects; D020780:Matrix Metalloproteinase 9 / Q000187:drug effects; D012907:Smoking / Q000009:adverse effects*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000187:drug effects; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000187:drug effects
chemical_list: D019715:Tissue Inhibitor of Metalloproteinase-1; D019716:Tissue Inhibitor of Metalloproteinase-2; D018093:Gelatinases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9